On the contrary, evidences tended to favor HDAraC in some trials: in Medical Research Council (MRC) AML 15 trial, halving dosage from 3 g/m 2 to 1.5 g/m 2 was associated with a strong trend towards a higher cumulative incidence of relapse 11 ; and a per protocol analysis in SAL AML 2003 trial showed an OS advantage in the single-agent HDAraC group 10 .
← all excerpts
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis.
1
—
—